Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

First 2022 GaBI Journal issue highlights / Professor Philip D Walson, MD

Letters to the Editor

No need for systematic switch studies to demonstrate interchangeability of biosimilars / Professor Pekka Kurki, MD, PhD, Finland


Substitution and interchangeability: time for a conversation? / Chad Rieger, MBA; Lisa Hall, PhD; David Lim, DPH, Australia

Original Research

On statistical evaluation for interchangeability of biosimilar products / Yuqi Li, BS Pharm; Professor Shein-Chung Chow, PhD

A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy / Federico J Piñeiro, Pharm, MPH, Fernández Argüelles Rogelio Alberto, Pharm, PhD

Review Articles

Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled? / M Buda, PhD, O Kolaj-Robin, PhD; E Charton, PhD

Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines / Professor Sia Chong Hock, BSc (Pharm), MSc; Adelia Pheh, BSc (Pharm) (Hon); Vimal Sachdeva, MSc; Associate Professor Chan Lai Wah, BSc (Pharm) (Hon), PhD

Long-acting insulin analogues. Drug selection by means of the System of Objectified Judgement Analysis (SOJA)Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled? / Robert Janknegt, PharmD, PhD, Marloes Dankers, MSc, PhD

Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps / Adjunct Associate Professor Sia Chong Hock, BSc (Pharm), MSc; Christine Koh, BSc (Pharm) (Hon); Associate Professor Chan Lai Wah, BSc (Pharm) (Hon), PhD


Biosimilarity is not a transitive property: implication for interchangeably, naming and pharmacovigilance / Pablo Matar, PhD, Argentina


Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD

Sponsored Article

Structural characterization methods for biosimilars: fit-for-purpose, qualified or validated / Richard L Easton, BSC (Hons), DIC, PhD

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Last update: 2022-08-01 Go Back Print

Comments are closed.